KIORA PHARMACEUTICALS, INC. Business Acquisition, Pro Forma Revenue
KIORA PHARMACEUTICALS, INC. (KPRX) reported Business Acquisition, Pro Forma Revenue of $952.18 thousand for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-23.
Discontinued › Income Statement › Other Income
us-gaap:BusinessAcquisitionsProFormaRevenue · last filed 2017-02-23
- KIORA PHARMACEUTICALS, INC. business acquisition, pro forma revenue for the quarter ending 2016-12-31 was $160.37K, a 207.44% increase year-over-year.
- KIORA PHARMACEUTICALS, INC. business acquisition, pro forma revenue for the quarter ending 2016-09-30 was $274.29K, a 12.47% increase year-over-year.
- KIORA PHARMACEUTICALS, INC. business acquisition, pro forma revenue for the quarter ending 2016-06-30 was $234.60K, a 659.89% increase year-over-year.
- KIORA PHARMACEUTICALS, INC. business acquisition, pro forma revenue for the quarter ending 2016-03-31 was $282.92K, a 87.30% increase year-over-year.
- KIORA PHARMACEUTICALS, INC. business acquisition, pro forma revenue for fiscal 2016 was $952.18K, a 99.22% increase from fiscal 2015.
- KIORA PHARMACEUTICALS, INC. business acquisition, pro forma revenue for fiscal 2015 was $477.96K.
| Period end | Business Acquisition, Pro Forma Revenue 3 month | Business Acquisition, Pro Forma Revenue 6 month | Business Acquisition, Pro Forma Revenue 9 month | Business Acquisition, Pro Forma Revenue 12 month |
|---|---|---|---|---|
| 2016-12-31 | $160.37K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | $434.66K derived: sum of 2 quarters · filed 2017-02-23 | $669.26K derived: sum of 3 quarters · filed 2017-02-23 | $952.18K 10-K · filed 2017-02-23 |
| 2016-09-30 | $274.29K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-01 | $508.89K derived: sum of 2 quarters · filed 2016-11-01 | $791.81K 10-Q · filed 2016-11-01 | $843.98K derived: sum of 4 quarters · filed 2017-02-23 |
| 2016-06-30 | $234.60K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-10 | $517.52K 10-Q · filed 2016-08-10 | $569.69K derived: sum of 3 quarters · filed 2017-02-23 | $813.56K derived: sum of 4 quarters · filed 2017-02-23 |
| 2016-03-31 | $282.92K 10-Q · filed 2016-05-13 | $335.09K derived: sum of 2 quarters · filed 2017-02-23 | $578.96K derived: sum of 3 quarters · filed 2017-02-23 | $609.83K derived: sum of 4 quarters · filed 2017-02-23 |
| 2015-12-31 | $52.16K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | $296.03K derived: sum of 2 quarters · filed 2017-02-23 | $326.90K derived: sum of 3 quarters · filed 2017-02-23 | $477.96K 10-K · filed 2017-02-23 |
| 2015-09-30 | $243.87K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-01 | $274.74K derived: sum of 2 quarters · filed 2016-11-01 | $425.79K 10-Q · filed 2016-11-01 | |
| 2015-06-30 | $30.87K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-10 | $181.92K 10-Q · filed 2016-08-10 | ||
| 2015-03-31 | $151.05K 10-Q · filed 2016-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |